Zdrowie i gospodarka · 08/04/2022

FDA Clears NASONEX Nasal Spray for Continued Sale

The FDA has determined that NASONEX nasal spray, 0.05mg/spray (50mcg), was not withdrawn from sale due to safety or effectiveness concerns, allowing it to remain on the market and paving the way for future abbreviated new drug applications (ANDAs).